Drugs Developed with Dutch Public Funding
This report examines the extent of Dutch public funding of drug development, through donations, loans and/or investments. This funding occurs both directly by financing development of new medicines, and indirectly through investments made into biotech companies, but channelled through universities, public research bodies, and national and regional investment funds.
A Dutch summary of the report is available as well.
read more less
Pfizer, BioNTech, Moderna, and Sinovac made an extraordinary USD 90 billion in profits on their COVID-19 vaccines and medicines in 2021 and 2022. SOMO’s new report Pharma’s Pandemic Profits shows that these enormous gains are…
In this letter, SOMO – together with a group of NGOs – urge the European Commission to drop provisions that protect intellectual property in the economic agreement (CEPA) between Indonesia-EU. They fear that the so…
SOMO, together with a broad coalition, have sent a letter to health attachés and to the Health Commissioner of the European Union urging them to reconsider crucial aspects of the recently launched Health Emergency Preparedness…
As some Development Assistance Committee (DAC) donors are considering using their Official Development Aid (ODA) budgets to cover expenditures related to Covid-19 vaccines, the work of the DAC is critical to ensure that ODA eligibility…
Vaccine manufacturer Moderna is employing tax avoidance structures to shift its profits to Switzerland and the US state of Delaware, research by SOMO in cooperation with Wemos. The European Union ordered $10.3 billion worth of…
Conditions attached to Dutch government investments in corona vaccines and medication to guarantee affordability and accessibility are are insufficient at best and, at worst, counterproductive. Vaccine manufacturing companies are able to negotiate conditions into the…
